Xeris Biopharma Holdings, Inc. is a pioneering force in the healthcare sector, revolutionizing injectable medications through innovative formulation and delivery technologies.

Xeris Biopharma Holdings Inc. has reported strong financial performance and raised its revenue guidance for 2025 to $260-275 million, driven by the success of its flagship product Recorlev.